FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:618-623 August 10, 2006 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article

Drug development is the process by which new therapies are created and brought to market to treat diseases. It is hard to imagine that such an activity would not be universally admired and lauded, but recently the pharmaceutical companies that develop new drugs have been criticized by patients, legislators, and the press.¹ This criticism has been focused on the high cost of prescription drugs and the disparity between the costs of these drugs in the United States and in other developed countries such as Canada and the United Kingdom.¹ In addition to concern about cost, a more recent issue is . . . [Full Text of this Article]

Lack of Long-Term Safety Data

Unmet Phase 4 Commitments

Lack of Clinically Meaningful End Points

Inadequate Incentives for Drug Development with High Commercial Risk

Incentives for the Development of Drugs for High-Need, High-Risk Areas

Incentives for Drugs That Are "First in Class"

Conclusions

Source Information

From the Vanderbilt University School of Medicine, Nashville.

Related Letters:

A New Approach to Drug Development
Guda H. E., Mayer D., Brown S., Frangioni J. V., Wood A. J.J.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2045-2046, Nov 9, 2006. Correspondence

This article has been cited by other articles:

• Ameer, B. (2008). Novel Trial Design: A Report From the 19th Frontiers Symposium of ACCP. J Clin Pharmacol 48: 793-798 [Abstract] [Full Text]  
• Kopetz, S., Overman, M., Chang, D. Z., Glover, K. Y., Shureiqi, I., Wolff, R. A., Abbruzzese, J. L., Eng, C. (2008). Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. JCO 26: 2000-2005 [Abstract] [Full Text]  
• De Palma, R., Liberati, A., Ciccone, G., Bandieri, E., Belfiglio, M., Ceccarelli, M., Leoni, M., Longo, G., Magrini, N., Marangolo, M., Roila, F. (2008). Developing Clinical Recommendations for Breast, Colorectal, and Lung Cancer Adjuvant Treatments Using the GRADE System: A Study From the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. JCO 26: 1033-1039 [Abstract] [Full Text]  
• Ray, W. A. (2008). Learning from Aprotinin -- Mandatory Trials of Comparative Efficacy and Safety Needed. NEJM 358: 840-842 [Full Text]  
• Psaty, B. M., Korn, D. (2007). Congress Responds to the IOM Drug Safety Report In Full. JAMA 298: 2185-2187 [Full Text]  
• Garattini, S., Bertele', V. (2007). How can we regulate medicines better?. BMJ 335: 803-805 [Full Text]  
• Psaty, B. M., Furberg, C. D. (2007). The Record on Rosiglitazone and the Risk of Myocardial Infarction. NEJM 357: 67-69 [Full Text]  
• Psaty, B. M., Furberg, C. D. (2007). Rosiglitazone and Cardiovascular Risk. NEJM 356: 2522-2524 [Full Text]  
• Garrison, L. P. Jr., Towse, A., Bresnahan, B. W. (2007). Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit Analysis. Health Aff (Millwood) 26: 684-695 [Abstract] [Full Text]  
• Bertino, J. S. Jr, Greenberg, H. E., Reed, M. D. (2007). American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process. J Clin Pharmacol 47: 418-422 [Full Text]  
• Arnon, S. S. (2007). Creation and Development of the Public Service Orphan Drug Human Botulism Immune Globulin. Pediatrics 119: 785-789 [Abstract] [Full Text]  
• Barbui, C, Cipriani, A (2007). Evidence-based psychopharmacology: an agenda for the future. Evid. Based Ment. Health 10: 4-6 [Full Text]  
• Belay, B., Belamarich, P. F., Tom-Revzon, C. (2007). The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. Pediatrics 119: 370-380 [Abstract] [Full Text]  
• Kaplan, N. M. (2007). Clinical Trials for Hypertension: Expectations Fulfilled and Unfulfilled. Hypertension 49: 257-259 [Full Text]  
• Horton, L. R (2007). Food and Drug Administration. BMJ 334: 55-56 [Full Text]  
• Fisher Wilson, J. (2006). Alterations in processes and priorities needed for new drug development.. ANN INTERN MED 145: 793-796 [Full Text]  
• Guda, H. E., Mayer, D., Brown, S., Frangioni, J. V., Wood, A. J.J. (2006). A New Approach to Drug Development. NEJM 355: 2045-2046 [Full Text]